A promising pilot clinical trial suggests that the bright yellow compound found in turmeric may help improve treatment outcomes in multiple myeloma when added to standard therapy. In this single-blinded randomized study involving 33 patients with transplant-ineligible multiple myeloma, researchers compared the usual chemotherapy combination of melphalan and prednisone (MP) to the same regimen with the addition of 8 grams of daily curcumin added for 28 days. 

The results were encouraging: the group receiving curcumin alongside MP saw a much higher overall remission rate compared with the control group. This suggests that curcumin may help to enhance how well standard chemo works. 

What might explain this effect? Curcumin is known for its anti-inflammatory, antioxidant, and anti-angiogenic properties, and in this trial, it was associated with significant reductions in certain markers known to help fuel cancer progression. These compounds are involved in inflammation, blood vessel growth, and cancer cell survival, so lowering their levels could help slow disease activity. 

It’s worth noting this was a small preliminary study, so larger trials are needed to  more strongly support the potential cancer-care benefits and understand long-term outcomes of curcumin. But the findings are exciting and reinforce the potential of natural compounds like curcumin to help support conventional cancer treatment strategies. 

Bottom line, curcumin may be a valuable, well-tolerated adjuvant alongside standard therapy in multiple myeloma, and is a bright example of how nature’s pharmacy can help complement modern medicine. 

Please note that the information provided in this blog post is for informational purposes only and should not be considered as medical advice. It is essential to consult with your healthcare provider or a qualified professional before making any healthcare decisions or taking any actions based on the information presented here.